Thomas Daniel, Celgene

2013 pay package: $7.2 million
2012 pay package: $3.6 million
Change: +100%
2013 compensation: $645,833 in salary; $1.1 million in stock awards; $2.3 million in option awards; $3.2 million in non-equity incentive plan compensation; $100,434 in other compensation

At Celgene, a rising tide raises all ships. The company exceeded its targets both financial and developmental in 2013, triggering a $3.2 million cash bonus for Thomas Daniel, president of research and early development, effectively doubling his total compensation and landing him on this list for the first time in his 7-year tenure at the Big Biotech.

The same model would seem to apply to Celgene's ($CELG) internal product engine. Fueled by the sales of its blockbuster multiple myeloma drug Revlimid--which brought in $4.3 billion last year--the company increased its R&D spend by 29% to $2.2 billion on the year, bankrolling a pipeline that's fast expanding thanks to Celgene's deal-friendly approach to R&D.

With Daniel at the helm, Celgene's R&D division committed millions in upfront fees and billions in biobucks to partner up on promising cancer, inflammation and gene therapies therapies from the likes of OncoMed ($OMED), MorphoSys and Acetylon. Internally, the company came through on label-expanding studies for its banner oncology and hematology drugs and scored a late-stage victory for the psoriasis-treating apremilast, leading to an April FDA approval for a drug many expect to be the next big thing at Celgene.

And the company isn't shying away from its deal-happy pedigree. So far in 2014, Celgene paid $710 million up front--the most in industry history--to get its hands on Nogra Pharma's late-stage Crohn's disease contender, and the biotech deepened its relationship with Forma Therapeutics through a buyout-option deal worth up to $600 million.

- here's Celgene's proxy

For more:
Celgene shells out $710M for a PhIII Crohn's drug with billions on the line
Celgene wins FDA approval for its blockbuster arthritis contender apremilast
Celgene doubles down on Forma with a $600M discovery deal tied to a buyout option

Thomas Daniel, Celgene

Suggested Articles

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.

The readout is a key moment in the history of the drug and Mirati, shares in which have soared in the updraft created by data on Amgen’s rival asset.